section name header

Pronunciation

o-sel-TAM-i-vir

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: neuraminidase inhibitors

Indications

REMS


Action

  • Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.
Therapeutic effects:
  • Reduced duration or prevention of flu-related symptoms.

Pharmacokinetics

Absorption: Rapidly absorbed from the GI tract; 75% reaches systemic circulation as the active drug.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Rapidly metabolized by the liver to oseltamivir carboxylate, the active drug. >99% excreted unchanged in urine.

Half-Life: Oseltamivir carboxylate: 6–10 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknownunknown12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: nausea, vomiting

Neuro: abnormal behavior, agitation, confusion, delirium, hallucinations, insomnia, nightmares, SEIZURES, vertigo

Resp: bronchitis

Interactions

Drug-drug:

Route/Dosage

Treatment of Influenza

Renal Impairment

Influenza Prevention

Renal Impairment

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Tamiflu